---
document_datetime: 2025-12-02 04:52:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/voriconazole-accord.html
document_name: voriconazole-accord.html
version: success
processing_time: 0.1276294
conversion_datetime: 2025-12-27 16:42:20.197044
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Voriconazole Accord

[RSS](/en/individual-human-medicine.xml/65476)

##### Authorised

This medicine is authorised for use in the European Union

voriconazole Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Voriconazole Accord](#more-information-on-voriconazole-accord-983)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Voriconazole Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Voriconazole Accord.

For practical information about using Voriconazole Accord, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Voriconazole Accord and what is it used for?

Voriconazole Accord is an antifungal medicine that contains the active substance voriconazole. It is used for the treatment of adults and children over the age of two years with:

- invasive aspergillosis (a type of fungal infection due to *Aspergillus* );
- candidaemia (another type of fungal infection due to *Candida* ) in non?neutropenic patients (patients with a normal white blood cell count);
- serious invasive *Candida* infections when the fungus is resistant to fluconazole (another antifungal medicine);
- serious fungal infections caused by *Scedosporium* or *Fusarium* (two different types of fungus).

When used for treating fungal infections, Voriconazole Accord is intended mainly for patients with worsening, possibly life-threatening, fungal infections.

Voriconazole Accord is also used to prevent fungal infections in patients who have had haematopoietic (blood) stem-cell transplantation (a transplant of a type of stem cells that can develop into blood cells) and are at high risk of infection.

Voriconazole Accord is a 'generic medicine'. This means that Voriconazole Accord is similar to a 'reference medicine' already authorised in the European Union (EU) called Vfend.

## How is Voriconazole Accord used?

Voriconazole Accord is available as tablets (50 mg or 200 mg). It is given twice a day. The dose of Voriconazole Accord depends on the weight of the patient. Patients need to receive an initial higher dose (loading dose) on the first day of treatment. The aim of the loading dose is to attain effective blood levels quickly. The loading dose is then followed by a maintenance dose that can be adjusted according to the patient's response. The dose may be increased or decreased according to how the patient responds.

The tablets are to be taken at least one hour before or after a meal. For full information, see the package leaflet. The medicine can only be obtained with a prescription.

## How does Voriconazole Accord work?

The active substance in Voriconazole Accord, voriconazole, is an antifungal medicine that belongs to the 'triazole' group. It works by preventing the formation of ergosterol, which is an important part of fungal cell membranes. Without ergosterol, the fungus is killed or prevented from spreading. The list of fungi against which Voriconazole Accord is active can be found in the summary of product characteristics (also part of the EPAR).

## How has Voriconazole Accord been studied?

Because Voriconazole Accord is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Vfend. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Voriconazole Accord?

Because Voriconazole Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Voriconazole Accord approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Voriconazole Accord has been shown to have comparable quality and to be bioequivalent to Vfend. Therefore, the CHMP's view was that, as for Vfend, the benefit outweighs the identified risks. The Committee recommended that Voriconazole Accord be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Voriconazole Accord?

A risk management plan has been developed to ensure that Voriconazole Accord is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Voriconazole Accord, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Voriconazole Accord

The European Commission granted a marketing authorisation valid throughout the European Union for Voriconazole Accord on 16 May 2013.

For more information about treatment with Voriconazole Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Voriconazole Accord : EPAR - Summary for the public

Reference Number: EMA/347883/2013

English (EN) (74.98 KB - PDF)

**First published:** 07/06/2013

**Last updated:** 15/03/2016

[View](/en/documents/overview/voriconazole-accord-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-559)

български (BG) (109.06 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/bg/documents/overview/voriconazole-accord-epar-summary-public_bg.pdf)

español (ES) (81.03 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/es/documents/overview/voriconazole-accord-epar-summary-public_es.pdf)

čeština (CS) (105.45 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/cs/documents/overview/voriconazole-accord-epar-summary-public_cs.pdf)

dansk (DA) (80.46 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/da/documents/overview/voriconazole-accord-epar-summary-public_da.pdf)

Deutsch (DE) (81.92 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/de/documents/overview/voriconazole-accord-epar-summary-public_de.pdf)

eesti keel (ET) (79.6 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/et/documents/overview/voriconazole-accord-epar-summary-public_et.pdf)

ελληνικά (EL) (112.77 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/el/documents/overview/voriconazole-accord-epar-summary-public_el.pdf)

français (FR) (81.54 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/fr/documents/overview/voriconazole-accord-epar-summary-public_fr.pdf)

hrvatski (HR) (99.95 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/hr/documents/overview/voriconazole-accord-epar-summary-public_hr.pdf)

italiano (IT) (80.2 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/it/documents/overview/voriconazole-accord-epar-summary-public_it.pdf)

latviešu valoda (LV) (101.6 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/lv/documents/overview/voriconazole-accord-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (103.5 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/lt/documents/overview/voriconazole-accord-epar-summary-public_lt.pdf)

magyar (HU) (101.09 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/hu/documents/overview/voriconazole-accord-epar-summary-public_hu.pdf)

Malti (MT) (106.47 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/mt/documents/overview/voriconazole-accord-epar-summary-public_mt.pdf)

Nederlands (NL) (81.27 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/nl/documents/overview/voriconazole-accord-epar-summary-public_nl.pdf)

polski (PL) (106.64 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/pl/documents/overview/voriconazole-accord-epar-summary-public_pl.pdf)

português (PT) (81.35 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/pt/documents/overview/voriconazole-accord-epar-summary-public_pt.pdf)

română (RO) (101.49 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/ro/documents/overview/voriconazole-accord-epar-summary-public_ro.pdf)

slovenčina (SK) (104.56 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/sk/documents/overview/voriconazole-accord-epar-summary-public_sk.pdf)

slovenščina (SL) (99.05 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/sl/documents/overview/voriconazole-accord-epar-summary-public_sl.pdf)

Suomi (FI) (80.06 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/fi/documents/overview/voriconazole-accord-epar-summary-public_fi.pdf)

svenska (SV) (80.52 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

15/03/2016

[View](/sv/documents/overview/voriconazole-accord-epar-summary-public_sv.pdf)

Voriconazole Accord : EPAR - Risk management plan

English (EN) (1.56 MB - PDF)

**First published:** 06/02/2024

[View](/en/documents/rmp-summary/voriconazole-accord-epar-risk-management-plan_en.pdf)

## Product information

Voriconazole Accord : EPAR - Product Information

English (EN) (617 KB - PDF)

**First published:** 07/06/2013

**Last updated:** 21/10/2025

[View](/en/documents/product-information/voriconazole-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-211)

български (BG) (849.09 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/bg/documents/product-information/voriconazole-accord-epar-product-information_bg.pdf)

español (ES) (767.6 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/es/documents/product-information/voriconazole-accord-epar-product-information_es.pdf)

čeština (CS) (829.98 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/cs/documents/product-information/voriconazole-accord-epar-product-information_cs.pdf)

dansk (DA) (784.35 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/da/documents/product-information/voriconazole-accord-epar-product-information_da.pdf)

Deutsch (DE) (576.65 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/de/documents/product-information/voriconazole-accord-epar-product-information_de.pdf)

eesti keel (ET) (747.11 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/et/documents/product-information/voriconazole-accord-epar-product-information_et.pdf)

ελληνικά (EL) (841.21 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/el/documents/product-information/voriconazole-accord-epar-product-information_el.pdf)

français (FR) (847.29 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/fr/documents/product-information/voriconazole-accord-epar-product-information_fr.pdf)

hrvatski (HR) (759.85 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/hr/documents/product-information/voriconazole-accord-epar-product-information_hr.pdf)

íslenska (IS) (766.95 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/is/documents/product-information/voriconazole-accord-epar-product-information_is.pdf)

italiano (IT) (920.43 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/it/documents/product-information/voriconazole-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (786.11 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/lv/documents/product-information/voriconazole-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (798.66 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/lt/documents/product-information/voriconazole-accord-epar-product-information_lt.pdf)

magyar (HU) (800.21 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/hu/documents/product-information/voriconazole-accord-epar-product-information_hu.pdf)

Malti (MT) (913.03 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/mt/documents/product-information/voriconazole-accord-epar-product-information_mt.pdf)

Nederlands (NL) (800.46 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/nl/documents/product-information/voriconazole-accord-epar-product-information_nl.pdf)

norsk (NO) (748.05 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/no/documents/product-information/voriconazole-accord-epar-product-information_no.pdf)

polski (PL) (814.96 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/pl/documents/product-information/voriconazole-accord-epar-product-information_pl.pdf)

português (PT) (1019.08 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/pt/documents/product-information/voriconazole-accord-epar-product-information_pt.pdf)

română (RO) (833.48 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/ro/documents/product-information/voriconazole-accord-epar-product-information_ro.pdf)

slovenčina (SK) (869.01 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/sk/documents/product-information/voriconazole-accord-epar-product-information_sk.pdf)

slovenščina (SL) (743.81 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/sl/documents/product-information/voriconazole-accord-epar-product-information_sl.pdf)

Suomi (FI) (850.75 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/fi/documents/product-information/voriconazole-accord-epar-product-information_fi.pdf)

svenska (SV) (785.36 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

21/10/2025

[View](/sv/documents/product-information/voriconazole-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000296347 17/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Voriconazole Accord : EPAR - All Authorised presentations

English (EN) (53.22 KB - PDF)

**First published:** 07/06/2013

**Last updated:** 11/01/2016

[View](/en/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-690)

български (BG) (97.89 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/bg/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (48.65 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/es/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (59.73 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/cs/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (46.35 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/da/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.3 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/de/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (50.07 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/et/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (81.55 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/el/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (48.89 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/fr/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (85.85 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/hr/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (50.04 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/is/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (50.8 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/it/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (76.48 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/lv/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (85.2 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/lt/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (82.51 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/hu/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (78.69 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/mt/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (52.14 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/nl/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (50.81 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/no/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (73.31 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/pl/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (50.6 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/pt/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (80.04 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/ro/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (75.47 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/sk/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (69.75 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/sl/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (53.6 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/fi/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (52.38 KB - PDF)

**First published:**

07/06/2013

**Last updated:**

11/01/2016

[View](/sv/documents/all-authorised-presentations/voriconazole-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Voriconazole Accord Active substance voriconazole International non-proprietary name (INN) or common name voriconazole Therapeutic area (MeSH)

- Aspergillosis
- Candidiasis
- Mycoses

Anatomical therapeutic chemical (ATC) code J02AC03

### Pharmacotherapeutic group

- Antimycotics for systemic use
- Triazole derivatives

### Therapeutic indication

Voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows:

- treatment of invasive aspergillosis;
- treatment of candidaemia in non-neutropenic patients;
- treatment of fluconazole-resistant serious invasive *Candida* infections (including *C. krusei* );
- Treatment of serious fungal infections caused by *Scedosporium* spp. and *Fusarium* spp.

Voriconazole Accord should be administered primarily to patients with progressive, possibly life-threatening infections.

## Authorisation details

EMA product number EMEA/H/C/002669

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Marketing authorisation issued 16/05/2013 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Voriconazole Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (150.21 KB - PDF)

**First published:** 12/05/2025

**Last updated:** 21/10/2025

[View](/en/documents/procedural-steps-after/voriconazole-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Voriconazole Accord : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (158.84 KB - PDF)

**First published:** 28/11/2013

**Last updated:** 12/05/2025

[View](/en/documents/procedural-steps-after/voriconazole-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Voriconazole Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/151290/2013

English (EN) (255.67 KB - PDF)

**First published:** 07/06/2013

**Last updated:** 07/06/2013

[View](/en/documents/assessment-report/voriconazole-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Voriconazole Accord

Adopted

Reference Number: EMA/151315/2013

English (EN) (75 KB - PDF)

**First published:** 22/03/2013

**Last updated:** 22/03/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-voriconazole-accord_en.pdf)

#### More information on Voriconazole Accord

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 21/10/2025

## Share this page

[Back to top](#main-content)